On Sept. 26, 2023, Dr. Sabine Gorynia, EVP GBA Group Pharma & Medical Devices, Torben Giese, Chief Strategy Officer GBA Group, and Felix Bunde, Managing Director GBA MDS, visited the new colleagues at ICCR Roßdorf GmbH.

GBA Group is expanding its range of toxicology services for customers in the chemical, medical device and pharmaceutical industries with the acquisition of ICCR-Roßdorf GmbH (ICCR-Roßdorf). This acquisition underlines GBA Group's ambition to position itself broadly as an international life science service provider through targeted portfolio expansions and investment in leading CROs.

"Global efforts in the area of health care will continue to grow in the future. With this in mind, GBA Group has significantly expanded its Pharma & Medical Devices portfolio and will continue to invest in this growth market to position itself as a professionally comprehensive and internationally positioned laboratory and service provider for the benefit of our society." Steffen Walter, CEO.

With the acquisition of the Finnish company Tampereen asbesti- ja kuitulaboratorio Oy (Taklab) by Labroc Oy (Labroc), GBA Group continues to expand its European network in the field of laboratory analysis for building pollutants.

At a time when a healthy lifestyle is becoming increasingly important for many consumers, dietary supplements are gaining significance. But how safe and necessary are they really, and which legal aspects need to be considered?

Learn more about these topics in our free webinar: "Dietary Supplements – Safe Products, Brand Protection & Legal Regulations" on 19.09.2023 from 15:00 – 16:00 online in Microsoft Teams.